Author: Anoma Ranaweera B.V. Sc; PhD (Clinical Biochemistry, University of Liverpool, UK). Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, May 2015.
Imatinib mesylate (Gleevac®; USA and Glivec® Europe, New Zealand, from Novartis) is a small molecule inhibitor of ABL, KIT, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases. It is an FDA-approved oral treatment for chronic myeloid leukaemia, acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative disease, chronic eosinophilic leukaemia and metastatic/malignant gastrointestinal stromal tumours. Imatinib has also been used for the treatment of some skin conditions.
Reported uses of imatinib in dermatology include:
With the exception of dermatofibrosarcoma protuberans, all other off-label dermatology indications are based on isolated case reports and/or small, uncontrolled series.
Imatinib has also been used in generalised morphoea.
Imatinib has been suggested if certain C-kit mutations present in certain types of melanoma;
Imatinib has also been reported to have been used successfully for:
The most frequently reported adverse reactions (>30%) are:
Common skin changes that occur during treatment with imatinib include:
Less common reactions include:
Some skin changes may be related to underlying haematological conditions, their treatment and/or immunosuppression:
See the DermNet NZ bookstore
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.